Chemo, radiation, and immunotherapy for lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of platinum-based chemotherapy, large fractionated radiotherapy, and the immunotherapy drug tislelizumab for people with stage IIIB to IV non-squamous non-small cell lung cancer. It aims to see if this approach can help control the cancer without certain gene mutations.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stage IIIB, IIIC, or IV non-squamous non-small cell lung cancer.
- Your tumor does not have certain gene changes (like EGFR, ALK, BRAF, ROS1, RET, MET) or targeted therapy has stopped working.
- You are able to take care of yourself (ECOG score 0-2).
- You have not had chemotherapy or other cancer treatment that ended less than 3 months before the cancer came back.
- You do not have uncontrolled autoimmune disease or a recent severe autoimmune reaction.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining the immunotherapy drug tislelizumab with radiation therapy for people with advanced non-squamous non-small cell lung cancer that hasn't been treated before. It aims to see if this combination helps control the cancer better than standard treatments.
This study tests a combination of three treatments—an immunotherapy drug called tislelizumab, chemotherapy, and a procedure called BACE—for advanced lung cancer that cannot be surgically removed. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests combining tumor ablation with the immunotherapy drug tislelizumab and chemotherapy before surgery for people with stage II–IIIB non-small cell lung cancer. The goal is to see if this combination helps remove the cancer more effectively.
This trial tests a combination of chemotherapy, radiation, and two targeted drugs (surufatinib and tislelizumab) for people with stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this approach works better than standard treatment.
This trial tests if adding the immunotherapy drug Tislelizumab to standard chemotherapy can shrink stage III non-small cell lung cancer that cannot be surgically removed at first. The goal is to see if this combination makes the cancer small enough for surgery.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy as a first treatment for people with stage IIIB or IIIC non-small cell lung cancer. The goal is to see if this approach can shrink the tumor before any other treatment.
Hear when a new Tislelizumab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.